Downloadable Slideset

Share

Program Content

Activities

  • ICI in Stage III NSCLC: Rationale
    Evaluating the Role of Immune Checkpoint Inhibitors in Unresectable Stage III NSCLC
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: April 27, 2018

    Expires: April 26, 2019

  • ICI in Stage III NSCLC: Efficacy
    Optimal Integration of Checkpoint Inhibitors Into the Management of Unresectable Stage III NSCLC
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: April 27, 2018

    Expires: April 26, 2019

  • ICI in Stage III NSCLC: irAE Management
    Strategies to Identify and Manage Immune-Mediated Adverse Events With Immune Checkpoint Inhibitors
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: April 27, 2018

    Expires: April 26, 2019

Faculty

cover img faculity

Mark M. Awad, MD, PhD

Assistant Professor
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

cover img faculity

Sandra Cuellar, PharmD, BCOP, FHOPA, FASHP

Clinical Oncology Pharmacist, UI Health
Clinical Associate Professor
University of Illinois at Chicago College of Pharmacy
Chicago, Illinois

cover img faculity

Ali McBride, PharmD, MS, BCOP, FAzPA

Clinical Coordinator
Department of Pharmacy
The University of Arizona Cancer Center
Tucson, Arizona

cover img faculity

Tarek Mekhail, MD, MSc, FRCSI, FRCSEd

Medical Director, Thoracic Cancer Program
Florida Hospital Medical Group
Orlando, Florida

Provided by

ProCE Banner

Supporters

AstraZeneca